All In Biotech

Drug Trial Radar · NCT06309485

Phase 2 Study of WGI-0301 for Advanced HCC

An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma as Second Line Therapy

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have previously received PD-1 / PD-L1 immune checkpoint inhibitors.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC)

Interventions

  • WGI-0301 at MTD/RP2D dose IV infusion, QWDrug

    WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

  • WGI-0301 at MTD/RP2D -1 dose IV infusion, QWDrug

    WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.

  • Sorafenib 400 mg PO, BID continuouslyDrug

    Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

  • Sorafenib 400 mg PO, BIDDrug

    Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1.Time frame: through study completion, an average of 2 year

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • West China Hospital Sichuan University

    Chengdu, China · Recruiting

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Jiangxi Cancer Hospital

    Nanchang, China · Not yet recruiting

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, China · Recruiting

  • China Pharmaceutical University, Shanghai Gobroad Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.